MAPLE GROVE, Minn. – Upsher-Smith has announced the recent launch of famotidine for oral suspension, USP. The famotidine oral suspension market had U.S. sales of approximately $73 million for the 12 months ending June 2023 according to IQVIA.
The Therapeutic Equivalence (TE) code for Upsher-Smith’s product is AB, and the original Reference Listed Drug (RLD) was the brand Pepcid (famotidine) for oral suspension.
This product launch is a result of Upsher-Smith’s strategic partnership with Appco Pharma LLC (Appco), a New Jersey-based generic drug development and manufacturing company.
